Sphingolipids in congenital diaphragmatic hernia; results from an international multicenter study by Snoek, K.G. (Kitty) et al.
RESEARCH ARTICLE
Sphingolipids in Congenital Diaphragmatic
Hernia; Results from an International
Multicenter Study
Kitty G. Snoek1*, Irwin K. M. Reiss2, Jeroen Tibboel1, Joost van Rosmalen3,
Irma Capolupo4, Arno van Heijst5, Thomas Schaible6, Martin Post7, Dick Tibboel1
1 Intensive Care and Department of Paediatric Surgery, Erasmus Medical Center- Sophia Children’s
Hospital, Rotterdam, The Netherlands, 2 Department of Neonatology, ErasmusMedical Center- Sophia
Children’s Hospital, Rotterdam, The Netherlands, 3 Department of Biostatistics, ErasmusMedical Center,
Rotterdam, The Netherlands, 4 Department of Medical and Surgical Neonatology, Bambino Gesù Children’s
Hospital, Rome, Italy, 5 Department of Neonatology, Radboud University Medical Centre, Nijmegen, The
Netherlands, 6 Department of Neonatology, UniversitätsklinikumMannheim, Mannheim, Germany, 7 Program
of Physiology and Experimental Medicine, Hospital for Sick Children Research Institute, Toronto, Canada
* k.snoek@erasmusmc.nl
Abstract
Background
Congenital diaphragmatic hernia is a severe congenital anomaly with significant mortality
and morbidity, for instance chronic lung disease. Sphingolipids have shown to be involved
in lung injury, but their role in the pathophysiology of chronic lung disease has not been
explored. We hypothesized that sphingolipid profiles in tracheal aspirates could play a role
in predicting the mortality/ development of chronic lung disease in congenital diaphragmatic
hernia patients. Furthermore, we hypothesized that sphingolipid profiles differ between ven-
tilation modes; conventional mechanical ventilation versus high-frequency oscillation.
Methods
Sphingolipid levels in tracheal aspirates were determined at days 1, 3, 7 and 14 in 72 neo-
nates with congenital diaphragmatic hernia, born after > 34 weeks gestation at four high-vol-
ume congenital diaphragmatic hernia centers. Data were collected within a multicenter trial
of initial ventilation strategy (NTR 1310).
Results
36 patients (50.0%) died or developed chronic lung disease, 34 patients (47.2%) by stratifi-
cation were initially ventilated by conventional mechanical ventilation and 38 patients
(52.8%) by high-frequency oscillation. Multivariable logistic regression analysis with correc-
tion for side of the defect, liver position and observed-to-expected lung-to-head ratio,
showed that none of the changes in sphingolipid levels were significantly associated with
mortality /development of chronic lung disease. At day 14, long-chain ceramides 18:1 and
24:0 were significantly elevated in patients initially ventilated by conventional mechanical
ventilation compared to high-frequency oscillation.
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Conclusions
We could not detect significant differences in temporal sphingolipid levels in congenital dia-
phragmatic hernia infants with mortality/development of chronic lung disease versus survivors
without development of CLD. Elevated levels of ceramides 18:1 and 24:0 in the conventional
mechanical ventilation group when compared to high-frequency oscillation could probably be
explained by high peak inspiratory pressures and remodeling of the alveolar membrane.
Introduction
In patients with congenital diaphragmatic hernia (CDH), lung related problems such as
chronic lung disease (CLD) and pulmonary vascular disease including pulmonary hyperten-
sion are the primary causes of mortality [1] with ventilator-induced lung injury (VILI) and
high concentrations of oxygen predisposing newborns to develop CLD as prime morbidity [2].
Since 2008, CDH neonates are treated according to the same neonatal treatment protocol,
developed during a consensus meeting of the CDH EURO Consortium [3]. Prenatally diag-
nosed CDH infants are intubated after birth and mechanically ventilated. Conventional
mechanical ventilation (CMV) and high-frequency oscillation (HFO) are two ventilation
modalities that are associated with VILI and thus predispose to developing CLD. In a random-
ized clinical trial (the VICI-trial) looking at initial ventilation strategy (CMV vs HFO) of prena-
tally diagnosed CDH infants, 41 of the 91 patients (45.1%) initially ventilated with CMV died
or had CLD by day 28 compared to 43 of the 80 patients (53.8%) using HFO [4]. This differ-
ence, however, did not reach statistical significance.
The exact mechanism for the development of CLD in CDH remains unknown. In postmor-
tem lung biopsies non-specific features as persistent inflammation, edema, vascular changes
and parenchymal fibrosis were observed after mechanical ventilation [5]. Due to changes in
treatment modalities over the years in premature born neonates, the so-called ‘new BPD’ devel-
oped, characterized by interrupted septation and abnormal vascularization, leading to fewer
and enlarged alveoli [6]. In contrast to premature born neonates, lungs of fetuses with CDH
are not surfactant deficient [7], and surfactant replacement therapy has no beneficial effect in
term neonates with CDH [8].
Sphingolipids are classically thought to be purely structural elements of the cell membrane,
but have been revealed as key bioactive mediators in a variety of pathophysiological processes
[9]. They have an important role as messenger molecule in the regulation of proliferation and
apoptosis [10]. Sphingolipids are involved in lung development, injury and repair as suggested
by elevated sphingolipid levels in brochoalveolar lavage of newborn rats exposed to hyperoxia
(injury model of CLD) which declined during subsequent ambient air exposure (repair) [11].
Various sphingolipids play an important role in cellular homeostasis. Ceramide leads to cell-
cycle arrest and apoptosis, whereas sphingosine-1-phosphate is involved in facilitating prolifer-
ation and differentiation of cells. The interplay between pro-apoptotic and apoptotic ‘rheostat’
determined the formation of lung structure, both macroscopically and on a cellular level, dur-
ing all stages of lung development [12].
Given the lack of knowledge on the pathogenesis of CLD in CDH, we have analyzed the
bronchoalveolar lavage for sphingolipids in tracheal aspirates at specific time-points during the
first month of a prospective ventilation study (VICI-trial) [4]. We hypothesized that sphingoli-
pid profiles could have a predictive role for mortality/ development of CLD. Secondly, we
aimed to determine whether CMV versus HFO ventilation leads to different sphingolipid levels
in CDH patients. These aims were achieved.
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Materials and Methods
Patient Population
Inborn neonates born between November 2008 and December 2013, after a gestation of more
than 34 weeks with a prenatal diagnosis of CDH, were included in a multicenter RCT of initial
ventilation strategy (NTR 1310)(4). Ethical approval was given by the medical ethics review
board of Erasmus MC, Rotterdam, the Netherlands (NTR 1310). Thereafter, all local medical
ethical committees gave their approval (Bambino Gesu Children's Hospital, Universitätsklini-
kumMannheim, Radboud University Medical Centre). Parents gave written informed consent.
The procedures, including obtaining informed consent, were conducted in accord with the eth-
ical standards of the Committee on Human Experimentation of the institution in which the
experiments were done. Exclusion criteria were: severe chromosomal anomaly such as trisomy
13 or 18, which may imply a decision to stop or not to start medical treatment; severe cardiac
anomalies expected to need corrective surgery in the first 60 days after birth; renal anomalies
associated with oligohydramnios; severe orthopedic and skeletal deformities which were likely
to influence thoracic or lung development; and severe anomalies of the central nervous system.
Patients with a gestational age of less than 34 weeks were excluded so that the results could not
be influenced by severe lung prematurity. Written parental informed consent was obtained
before birth. All children were treated according to the same standardized protocol [3]. Patients
were randomized for initial ventilation strategy (CMV or HFO) within two hours after birth.
CLD was defined as oxygen dependency (>21%) at day 28 as described by Jobe and Bancalari
[13]. Diaphragmatic defect size was classified according to the definition of the CDH study
group and assessed during surgical repair [14].
Tracheal Aspirates
Tracheal aspirates were obtained during routine tracheal suctioning within the first 24 hours of
life and at day 3, 7, and 14. Tracheal aspirates were only collected during the period of mechan-
ical ventilation. During tracheal suctioning, flushing with 0.5–1.0 ml saline was performed
according to standard practice. Tracheal aspirates were immediately centrifuged at 1500g for 6
minutes at 20°C and samples were stored at -80°C until analysis.
Sphingolipid measurements
Sphingolipids were measured as previously described [11]. Briefly, lipids were extracted from
tracheal aspirate samples and sphingolipids were separated and analyzed using high perfor-
mance liquid chromatography and tandem mass spectrometry (LC-MS/MS). The analyses
were performed at the Analytical Facility for Bioactive Molecules of the Hospital for Sick Chil-
dren, Toronto, ON, Canada. Sphingolipid levels were presented as ng/mL.
Statistical analysis
Patient characteristics were described as number (%) for categorical variables, mean ± SD for
normally distributed variables or median (interquartile range; IQR) for continuous variables
that were not normally distributed. Patient characteristics between participants and non-par-
ticipants were analyzed using independent samples t-test for continuous data or chi square
tests for categorized data. Sphingolipid levels were compared between patients who died/ devel-
oped CLD and patients who survived/ did not develop CLD, and between patients who were
initially ventilated by CMV and HFO by using the Mann-Whitney U test. All analyses were
performed for each of the four time points separately. Independent associations between sphin-
golipids levels and mortality/ development of CLD were determined using multivariable
Sphingolipids in CDH; An International Multicenter Study
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logistic regression modelling and were presented as odds ratio (OR) [95% confidence interval],
p-value. Observed-to-expected lung-to-head ratio (O/E LHR), side of the defect, liver position,
center and ventilation mode were included as independent variables in these models. Sphingo-
lipid levels were logarithmically transformed due to skewed distribution, and non-detectable
values were set to the lower detection threshold 0.03 ng/mL. The calibration of the multivari-
able logistic regression models was assessed using the Hosmer-Lemeshow goodness-of-fit test.
All statistical tests, except for the analyses to determine difference in patients characteristics
between participants and non-participants, were two-sided and used a Bonferroni-adjusted sig-
nificance level of 0.0125 to correct for multiple testing at the four time points. All analyses were
performed using SPSS version 21.0 for Windows statistical software.
Results
Tracheal aspirates were collected in 69 patients of the 171 infants who were included in the
RCT at the four participating centers. Additionally, in three patients from one center there was
only written consent for sample collection, and not for randomization of initial ventilation
mode. Thus, tracheal aspirates from 72 patients were collected at various time-points. 179 tra-
cheal aspirates were obtained, of which 49 were collected at day 1, 56 samples at day 3, 46 sam-
ples at day 7, and 21 samples at day 14. Patients who had tracheal aspirates collected showed
an increased prevalence of left-sided diaphragm defect compared to the patients who had no
aspirates collected (Table 1). Of the 72 included patients, 16 patients (22.2%) died in the first
year of life, and 20 of the 56 survivors (35.7%) developed CLD; thus, 36 patients (50.0%) died/
developed CLD. Thirty-eight patients (52.8%) were initially ventilated by HFO and 34 patients
(47.2%) by CMV.
No significant differences in sphingolipid profiles were found at day 1, 3, 7 and 14 between
patients who died/ developed CLD and patients who survived/did not develop CLD (Table 2).
Conclusions were not different after exclusion of the five FETO-treated patients (results not
shown). Median sphingolipid levels over time for each sphingolipid are presented in Fig 1.
Multivariable logistic regression analysis with correction for O/E LHR, side of the defect, liver
position, center and ventilation mode showed that none of the sphingolipid levels were associ-
ated with mortality/development of CLD (Table 3). Conclusions were not different after exclu-
sion of the five FETO-treated patients (results not shown). The p-values of the Hosmer-
Lemeshow test were larger than 0.05, indicating an adequate model calibration.
No significant differences in sphingolipid profiles were found at days 1, 3, and 7 between
patients who were initially ventilated by CMV versus HFO (Table 4). At day 14, ceramide-
C18:1 and ceramide-C24:0 were increased for patients initially ventilated by CMV (median 1.4
(IQR 1.1–4.3))and (median 81.0 (IQR 33.6–205.2)) respectively compared to HFO (median 0.5
(0.0–1.1)) (p = 0.005) and (median 25.3 (IQR 2.9–53.0)) respectively (p = 0.008). In a selection
of patients who died/ developed CLD, at day 14 ceramide-C18:1 was increased for patients ini-
tially ventilated by CMV (median 1.4 (IQR 1.2–5.6)) compared to HFO (median 0.5 (0.1–1.1))
(p = 0.009), but ceramide-C24:0 was significantly increased in patients initially ventilated by
CMV (median 102.5 (IQR 31.3–225.9)) compared to HFO (median 23.3 (IQR 6.4–33.7))
(p = 0.011).
Discussion
In this prospective international multicenter study, we determined sphingolipid levels in tra-
cheal aspirates of antenatally diagnosed CDH patients in the neonatal period. We found no sig-
nificant differences in temporal sphingolipid profiles between patients who died/developed
CLD compared to patients who survived/did not develop CLD. Furthermore, no significant
Sphingolipids in CDH; An International Multicenter Study
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sphingolipid differences were found between patients initially ventilated by CMV compared to
patients initially ventilated by HFO except for ceramide-C18:1 and ceramide-C24:0 at day 14.
Bioactive sphingolipids have been investigated regarding their role in respiratory diseases
such as asthma [15] and COPD [16]. Moreover, sphingolipids are important factors in lung
development and disease [9], and recently have been shown to play a role in the pathogenesis
of CLD in mice [17].
In lungs of preterm infants who were ventilated or received oxygen treatment, epithelial cell
apoptosis and proliferation of epithelial, endothelial and smooth muscle cells were observed
[18]. Various sphingolipids play an important role in cellular homeostasis. Ceramide leads to
cell-cycle arrest and apoptosis, whereas sphingosine-1-phosphate is involved in facilitating pro-
liferation and differentiation of cells. The interplay between pro-apoptotic and apoptotic ‘rheo-
stat’ determined the formation of lung structure, both macroscopically and on a cellular level,
during all stages of lung development. Since we did not find any significant difference in sphin-
golipid levels in tracheal aspirates of CDH patients, it seems that the role of sphingolipids in
the pathophysiology of CLD is different in CDH patients when compared to for instance pre-
mature born neonates. The finding that lungs of fetuses with CDH are not surfactant deficient
[7] supports this idea. No beneficial effect of surfactant replacement therapy has been shown in
term neonates with CDH [8], nor in CDH neonates on ECMO [19]. Even in prematurely born
neonates with CDH, surfactant replacement therapy did not improve survival rates [20]. The
predisposing risk factors for CLD also vary between neonates with CDH and preterm born
Table 1. Patient characteristics.
Included patients n = 72 Non-included patients n = 102 p-value
Gestational age (weeks) 38.0± 1.2 37.9± 1.4 0.66
Birth weight (grams) 2957± 443 2901± 467 0.43
Fetoscopic endotracheal occlusion 5 (6.9%) 14 (13.7%) 0.16
Male gender 33 (45.8%) 51 (50.0%) 0.59
Left sided defect 68 (94.4%) 83 (81.4%) 0.01
Liver position: intrathoracic 37 (51.4%) 66 (64.7%) 0.08
Type of repair 0.06
Patch correction 48 (66.7%) 46 (45.1%)
Primary closure 19 (26.4%) 35 (34.3%)
No repair 5 (6.9%) 21 (20.6%)
Diaphragmatic defect size 0.05
A 5 (6.9%) 7 (6.9%)
B 5 (6.9%) 28 (27.4%)
C 21 (29.2%) 34 (33.3%)
D 35 (48.7%) 10 (9.8%)
No repair 5 (6.9%) 21 (20.6%)
Treatment with nitric oxide 33 (45.8%) 53 (52.0%) 0.43
ECMO (if ECMO was available) 22/ 56 (39.3%) 20/ 55 (36.4%) 0.76
Treatment with inotropics 60 (83.3%) 89 (87.2%) 0.47
Age at repair (days) 5.0 (3.0–9.0) 4.0 (3.0–6.0) 0.28
Ventilation time (days) 15.0 (7.8–23.0) 10.0 (7.0–17.5) 0.29
ICU admission (days) 22.5 (15.3–39.8) 20.5 (13.0–40.5) 0.99
Data are presented as n (%), mean± SD or median (IQR). Abbreviations: ECMO: extracorporeal membrane oxygenation. HFO: high-frequency oscillation;
ICU: intensive care unit.
doi:10.1371/journal.pone.0155136.t001
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Table 2. Associations of sphingolipids with outcomemortality/ development of CLD.
Day 1 Day 3 Day 7 Day 14
Independent
variable
Median (IQR) p-
value
Median (IQR) p-
value
Median (IQR) p-
value
Median (IQR) p-
value
Cer 14:0 0.37 0.35 0.76
No CLD or alive 6.6 (3.0–14.6) 4.5 (2.7–10.8) 3.0 (1.5–7.3) 3.5 (0.8–8.0)
CLD or died 10.7 (5.1–20.0) 7.2 (2.6–14.5) 3.2 (0.9–13.2) 3.9 (1.9–8.7)
Cer 16:0 0.70 0.73 0.43 0.97
No CLD or alive 214.5 (144.1–
487.8)
227.0 (118.4–380.4) 192.0 (114.0–
730.0)
343.0 (81.6–649.1)
CLD or died 328.0 (120.0–
612.0)
240.8 (133.9–504.8) 147.5 (48.0–565.0) 306.5 (122.5–781.9)
Cer 18:0 0.86 0.90 0.50 0.90
No CLD or alive 71.2 (41.9–176.4) 83.2 (45.5–167.1) 81.0 (45.2–268.0) 197.5 (50.5–278.8)
CLD or died 112.5 (33.7–265.5) 96.5 (43.5–164.8) 60.5 (15.5–183.5) 124.5 (37.0–339.4)
Cer 18:1 0.57 0.78 0.61 0.64
No CLD or alive 0.9 (0.3–2.0) 0.8 (0.5–1.8) 0.7 (0.2–2.9) 0.9 (0.2–1.7)
CLD or died 1.8 (0.1–3.5) 1.1 (0.4–2.7) 1.4 (0.1–3.4) 1.1 (0.4–2.5)
Cer(DiHy)16:0 0.61 0.64 0.60 0.93
No CLD or alive 27.6 (14.1–73.0) 31.4 (15.4–60.0) 30.1 (12.4–53.0) 98.9 (1.3–196.5)
CLD or died 40.0 (12.5–104.3) 33.1 (14.7–92.5) 14.7 (4.5–84.6) 29.9 (18.8–97.8)
Cer(DiHy)18:0 0.67 0.94 0.53 0.52
No CLD or alive 8.3 (3.7–17.7) 15.3 (7.0–22.8) 8.6 (3.3–36.2) 20.6 (5.3–64.5)
CLD or died 12.2 (2.8–31.3) 13.3 (7.3–31.5) 5.6 (2.1–26.3) 10.8 (5.7–29.5)
Cer(DiHy)18:1 0.35 0.93 0.04 0.97
No CLD or alive 0.03 (0.03–0.03) 0.03 (0.03–0.03) 0.03 (0.03–0.03) 0.03 (0.03–0.56)
CLD or died 0.03 (0.03–0.30) 0.03 (0.03–0.03) 0.03 (0.03–1.21) 0.03 (0.03–0.13)
Cer 20:0 0.69 0.46 0.46 0.90
No CLD or alive 27.5 (15.6–67.9) 24.8 (14.1–52.2) 23.2 (15.0–94.5) 74.5 (16.3–105.5)
CLD or died 39.3 (14.1–108.0) 33.6 (20.2–58.2) 20.0 (5.4–66.5) 45.7 (14.0–122.2)
Cer 22:0 0.59 0.16 0.65 0.83
No CLD or alive 32.8 (18.0–88.5) 41.8 (14.6–67.9) 32.8 (16.0–137.5) 57.5 (14.7–109.9)
CLD or died 43.5 (17.7–198.8) 68.3 (24.4–91.9) 33.6 (3.9–108.5) 35.1 (20.0–130.5)
Cer 24:0 0.42 0.16 0.76 0.89
No CLD or alive 46.2 (24.7–122.5) 44.1 (17.1–105.0) 37.5 (14.4–217.5) 54.8 (14.6–114.6)
CLD or died 69.5 (25.3–340.3) 83.3 (24.5–161.0) 43.5 (4.4–125.5) 36.0 (23.1–102.3)
Cer 24:1 0.52 0.23 0.65 0.90
No CLD or alive 62.5 (36.1–174.5) 78.0 (27.5–157.3) 51.5 (29.9–449.5) 140.3 (32.3–343.4)
CLD or died 102.0 (32.7–352.0) 133.8 (49.3–196.6) 64.0 (10.0–203.5) 104.5 (40.7–306.5)
Cer(DiHy)24:0 0.96 0.31 0.48 0.41
No CLD or alive 5.7 (2.8–13.2) 3.3 (1.2–6.7) 3.1 (0.8–11.0) 5.3 (2.1–11.3)
CLD or died 6.1 (2.5–22.8) 5.2 (1.6–12.2) 2.6 (0.3–11.4) 1.5 (1.0–8.9)
Cer(DiHy)24:1 0.42 0.25 0.88 0.90
No CLD or alive 4.4 (1.6–16.2) 8.4 (2.5–15.4) 4.8 (1.2–29.7) 8.2 (1.3–39.9)
CLD or died 9.5 (2.0–20.7) 10.1 (2.4–25.3) 7.1 (0.8–25.9) 5.6 (1.6–16.6)
SM12:0 0.53 0.06 1.00 0.97
No CLD or alive 2.3 (1.2–3.7) 0.9 (0.5–1.8) 0.9 (0.3–2.2) 1.4 (0.2–3.2)
CLD or died 2.0 (1.1–4.4) 1.6 (0.6–3.3) 1.0 (0.3–2.2) 0.7 (0.6–2.0)
SM(DiHy)12:0 0.59 0.45 0.30 0.36
(Continued)
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neonates; for example, chorioamnionitis being associated with premature birth and an
increased risk of developing BPD [21] is absent in CDH. Chorioamnionitis is an inflammatory
process and sphingolipids being involved in the regulation of inflammation [12], underscore a
role for sphingolipids in the pathophysiology of CLD in premature infants.
Another possibility is that the lung hypoplasia seen in CDH leads to less production of cer-
amides essential for lung development. To solve this problem other causes of pulmonary hypo-
plasia should be investigated such as obstructive uropathy, but these data are neither available
in our biobank nor in the literature. Besides data obtained from patients with other causes of
lung hypoplasia, animal models of lung hypoplasia may be informative. Zimmer et al studied
nitrofen-induced CDH rats, and performed QRT-PCR, western blotting and confocal-immu-
nofluorescence microscopy to reveal pulmonary gene and protein expression levels of sphingo-
sine kinase 1, sphingosine-1-phosphate 1, 2, 3 and Ras-related C3 botulinum toxin substrate 1
(Rac1) [22]. They found that pulmonary gene expression of sphingosine-1-phosphate 1 and
Rac1 was significantly increased in the CDH group compared to controls, whereas sphingo-
sine-1-phosphate 2 and 3 expression was decreased. Therefore, they concluded that sphingo-
sine-1-phosphate 1 and Rac1 are important mediators of pulmonary hypoplasia in this model.
Therefore, these factors should be included in future studies in CDH patients.
Fetal lung development occurs in a relative hypoxic environment that stimulates vascular
development viaHypoxia Inducible Factors (HIFs) [23]. HIFs upregulate genes necessary for
proper lung vascular and alveolar development [24]. Most deaths among CDH patients are due
Table 2. (Continued)
Day 1 Day 3 Day 7 Day 14
Independent
variable
Median (IQR) p-
value
Median (IQR) p-
value
Median (IQR) p-
value
Median (IQR) p-
value
No CLD or alive 0.4 (0.3–0.7) 0.3 (0.2–0.5) 0.4 (0.2–0.6) 0.8 (0.2–1.5)
CLD or died 0.6 (0.3–1.0) 0.3 (0.2–0.8) 0.2 (0.1–0.5) 0.3 (0.1–0.7)
SM16:0 0.89 0.69 0.43 0.64
No CLD or alive 595.0 (355.1–
1053.8)
808.5 (520.0–1247.5) 660.0 (497.5–
1862.0)
1365.0 (311.9–
1722.5)
CLD or died 630.0 (300.5–
1352.5)
953.3 (411.6.61–
1701.3)
810.0 (122.5–
1385.0)
955.0 (518.3–
1577.5)
SM18:0 0.75 0.62 0.82 0.97
No CLD or alive 122.5 (71.4–259.3) 201.3 (91.8–300.8) 150.0 (82.0–325.0) 269.5 (64.5–346.5)
CLD or died 119.5 (60.0–296.5) 259.5 (86.3–387.5) 223.5 (30.9–360.0) 176.0 (103.8–409.9)
SM18:1 0.93 0.30 0.65 0.97
No CLD or alive 28.3 (15.6–57.7) 27.2 (14.7–56.3) 15.8 (9.3–51.5) 23.8 (5.4–70.5)
CLD or died 24.0 (12.4–85.5) 47.0 (14.3–119.1) 36.5 (4.0–82.1) 19.5 (8.0–41.7)
SM24:0 0.91 0.59 0.73 0.97
No CLD or alive 263.0 (124.6–
585.3)
410.5 (203.0–661.3) 360.0 (180.5–
982.0)
469.0 (122.8–571.3)
CLD or died 272.0 (122.8–
761.0)
496.3 (241.0–797.0) 349.5 (69.5–
1020.0)
341.5 (232.3–630.0)
SM24:1 0.83 0.61 0.51 0.97
No CLD or alive 215.8 (102.4–
410.7)
357.3 (187.1–680.0) 409.0 (183.5–
1116.0)
745.0 (105.9–
1278.8)
CLD or died 176.5 (80.8–535.0) 464.0 (172.6–877.3) 510.0 (62.0–
1025.0)
530.0 (219.0–
1107.5)
Sphingolipids were expressed as ng/mL. Abbreviations: CLD: chronic lung disease; IQR: interquartile range; Cer: ceramide; SM: sphingomyelin.
doi:10.1371/journal.pone.0155136.t002
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Fig 1. Median values of sphingolipids over time.Grey: No CLD or alive. Black: CLD or died.
doi:10.1371/journal.pone.0155136.g001
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to severe pulmonary hypertension. It was recently shown that ceramide upregulation was asso-
ciated with decreased Vascular Endothelial Growth Factor (VEGF) expression via suppression
of HIF-1α, suggesting a role for sphingolipids in VEGF regulation [25]. Since VEGF has an
important role in pulmonary vascular development, and it was shown that increased plasma
VEGF-A correlates with clinical severity of pulmonary vascular disease in CDH infants [26],
this mechanism could be involved in CDH patients. Our study design, however, did not pro-
vide for measuring VEGF plasma levels to test this hypothesis.
When we compared tracheal aspirate sphingolipids levels for the initial ventilation strategy,
HFO versus CMV, we found no differences between the two ventilation modalities at day 1, 3
and 7. However, at day 14, two long chain ceramides (ceramide-C18:1 and ceramide-C24:0)
were significantly elevated in patients initially ventilated by CMV when compared to HFO. It is
remarkable that only at day 14 significant differences were observed. One explanation may be
that in CMV the use of high peak inspiratory pressures and shear stress over time lead to
sphingomyelinase activation and sphingomyelin degradation to ceramides. Alternatively, it is
plausible that CMV increases over time de novo ceramide synthesis. Unfortunately, the study
design did not allow inclusion of a non-ventilated control group or healthy pulmonary controls
and, therefore, we do not know whether ceramide levels were increased by either ventilation
modality. Ceramides enhance apoptosis and decrease vascular barrier integrity [27]. Of note,
increased apoptosis has been found in epithelial cells of CLD patients, but whether this was
triggered by ceramides was not investigated [28]. In the current study, the increase in very
Table 3. Multivariable logistic regression analysis with outcomemortality/ development of CLD.
DAY 1 DAY 3 DAY 7
Independent variable OR 95% CI OR 95% CI OR 95% CI
Cer 14:0 0.826 0.457–1.495 1.718 0.654–4.516 1.055 0.581–1.916
Cer 16:0 0.713 0.364–1.397 1.269 0.527–3.059 0.969 0.509–1.846
Cer 18:0 0.709 0.389–1.294 0.930 0.384–2.255 0.872 0.463–1.643
Cer 18:1 0.642 0.345–1.193 1.447 0.697–3.005 1.047 0.667–1.644
Cer(DiHy)16:0 0.452 0.135–1.511 2.854 0.519–15.694 0.970 0.470–2.001
Cer(DiHy)18:0 0.453 0.193–1.061 1.191 0.451–3.151 0.939 0.569–1.548
Cer(DiHy)18:1 1.433 0.710–2.893 1.040 0.469–2.304 1.267 0.704–2.282
Cer 20:0 0.692 0.358–1.337 1.016 0.428–2.407 0.893 0.481–1.660
Cer 22:0 0.744 0.400–1.385 1.290 0.605–2.750 0.964 0.568–1.634
Cer 24:0 0.802 0.456–1.410 1.531 0.681–3.442 0.957 0.635–1.442
Cer 24:1 0.801 0.459–1.399 1.369 0.645–2.902 0.978 0.587–1.628
Cer(DiHy)24:0 0.650 0.391–1.080 1.369 0.699–2.681 0.901 0.558–1.454
Cer(DiHy)24:1 0.787 0.497–1.245 1.175 0.653–2.113 1.059 0.753–1.489
SM12:0 0.611 0.270–1.380 1.446 0.444–4.705 1.116 0.641–1.943
SM(DiHy)12:0 0.942 0.362–2.448 0.936 0.323–2.717 0.880 0.401–1.932
SM16:0 0.444 0.142–1.382 0.750 0.212–2.654 0.917 0.489–1.720
SM18:0 0.496 0.186–1.324 0.924 0.363–2.349 0.934 0.473–1.846
SM18:1 0.754 0.418–1.361 1.019 0.461–2.252 1.123 0.639–1.973
SM24:0 0.542 0.214–1.374 0.958 0.369–2.483 0.920 0.529–1.601
SM24:1 0.636 0.311–1.300 0.988 0.394–2.477 0.919 0.520–1.624
Abbreviations: CLD: chronic lung disease; OR: odds ratio; CI: conﬁdence interval; Cer; ceramide; SM: sphingomyelin. Observed-to-expected lung-to-head
ratio, side of the defect, liver position, center and ventilation arm were included as independent variables. Day 14: too limited number of observations to
perform multivariable logistic regression analysis.
doi:10.1371/journal.pone.0155136.t003
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Table 4. Sphingolipid levels for initial ventilation (CMV or HFO).
Day 1 Day 3 Day 7 Day 14
Independent
variable
Median (IQR) p-
value
Median (IQR) p-
value
Median (IQR) p-
value
Median (IQR) p-
value
Cer 14:0 0.98 0.54 0.90 0.05
CMV 7.8 (3.0–17.4) 6.2 (2.7–13.7) 0.3 (1.1–13.2) 6.9 (2.9–11.0)
HFO 8.2 (3.6–18.0) 5.2 (2.3–13.7) 3.2 (0.9–9.4) 2.6 (0.4–4.6)
Cer 16:0 0.98 0.44 0.68 0.06
CMV 266.5 (112.0–
534.8)
242.0 (148.4–
485.9)
151.0 (47.8–695.0) 505.6 (261.0–931.3)
HFO 256.5 (147.5–
548.0)
225.0 (109.6–
395.6)
204.5 (66.4–550.0) 202.5 (17.9–348.0)
Cer(DiHy)16:0 0.71 0.64 0.87 0.22
CMV 32.2 (9.3–83.1) 33.1 (16.5–71.0) 20.1 (8.3–78.3) 30.6 (20.0–175.5)
HFO 38.3 (16.5–87.6) 30.8 (11.7–78.5) 27.5 (4.6–62.0) 24.2 (2.5–32.5)
Cer 18:0 0.92 0.06 0.65 0.07
CMV 86.3 (32.3–244.8) 120.0 (59.1–183.6) 50.0 (15.5–268.0) 253.4 (101.4–392.6)
HFO 81.5 (44.9–189.0) 73.3 (37.5–145.3) 82.5 (19.9–192.5) 94.0 (5.4–195.0)
Cer 18:1 0.93 0.77 0.91 0.005
CMV 1.0 (0.5–2.6) 0.8 (0.6–2.2) 0.7 (0.1–3.4) 1.4 (1.1–4.3)
HFO 0.9 (0.3–3.4) 1.0 (0.1–2.1) 0.8 (0.2–3.0) 0.5 (0.0–1.1)
Cer(DiHy)18:0 0.36 0.29 0.72 0.08
CMV 6.0 (2.3–22.5) 16.9 (7.0–31.9) 5.0 (2.2–26.3) 22.0 (9.4–38.2)
HFO 9.8 (4.1–29.4) 12.7 (7.2–20.0) 9.6 (2.2–27.6) 9.2 (1.0–18.8)
Cer(DiHy)18:1 0.72 0.89 0.58 0.05
CMV 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–1.2) 0.1 (0.0–1.2)
HFO 0.03 (0.03–0.03) 0.03 (0.03–0.03) 0.03 (0.03–0.55) 9.2 (3.7–16.3)
Cer 20:0 0.83 0.26 0.62 0.11
CMV 33.3 (12.2–89.6) 38.8 (19.3–56.1) 17.3 (4.7–94.5) 85.7 (35.9–144.6)
HFO 31.6 (20.0–81.4) 27.7 (12.9–54.5) 31.2 (7.6–66.5) 31.8 (1.7–69.0)
Cer 22:0 0.80 0.81 0.68 0.04
CMV 46.0 (15.3–98.1) 41.8 (19.5–91.6) 25.3 (6.2–137.5) 79.1 (33.8–164.6)
HFO 33.3 (20.9–108.5) 47.5 (14.6–86.3) 59.0 (10.5–108.5) 22.0 (1.9–55.0)
Cer 24:0 0.65 0.95 0.64 0.008
CMV 69.0 (20.9–132.5) 51.5 (18.1–114.4) 31.1 (5.7–217.5) 81.0 (33.6–205.2)
HFO 46.3 (26.5–132.0) 54.2 (16.3–154.1) 53.8 (8.3–125.5) 25.3 (2.9–53.0)
Cer 24:1 0.95 0.81 0.67 0.02
CMV 87.8 (28.0–201.9) 80.5 (31.6–177.9) 51.5 (10.7–397.0) 247.0 (89.0–437.8)
HFO 65.5 (40.9–172.0) 80.5 (27.6–190.8) 110.0 (14.2–203.5) 48.3 (5.8–139.5)
Cer(DiHy)24:0 0.63 0.97 0.97 0.06
CMV 6.2 (2.5–18.0) 4.1 (1.6–8.0) 2.6 (0.8–10.7) 7.1 (1.4–13.9)
HFO 4.8 (2.7–7.7) 3.9 (1.3–11.2) 3.1 (0.3–13.6) 1.1 (1.0–5.1)
Cer(DiHy)24:1 0.85 0.91 0.67 0.05
CMV 9.3 (1.6–17.2) 8.6 (3.4–15.5) 7.1 (3.5–25.9) 11.6 (3.3–42.7)
HFO 4.7 (1.9–16.6) 9.9 (2.2–19.9) 5.7 (0.8–25.9) 3.8 (0.0–9.5)
SM12:0 0.14 0.40 0.95 0.11
CMV 2.7 (1.4–5.4) 1.2 (0.6–2.4) 0.9 (0.3–2.2) 1.2 (0.6–2.7)
HFO 2.0 (1.0–2.8) 1.0 (0.4–2.1) 1.2 (0.3–2.2) 0.6 (0.1–1.2)
SM(DiHy)12:0 0.67 0.68 0.41 0.22
(Continued)
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long-chain (C24:0) ceramides, known to stimulate cell proliferation and not apoptosis [29], fits
with the favorable clinical outcomes in the CMV group when compared to HFO [4].
To our knowledge this is the first study investigating lung sphingolipid metabolism in CDH
patients. Unique is the prospective multicenter design in a relatively large cohort of patients.
Secondly, apart from the initial ventilation strategy, all children were treated according to the
same study protocol [3]. A few limitations should be considered. Firstly, patient characteristics
between patients of whom samples were collected and patients of whom no samples were col-
lected, were different with respect to the side of the defect, although a recent multicenter study
found that morbidity following repair of right-sided CDH was not significantly different from
that in left-sided CDH survivors [30]. Therefore we believe that there was no bias in patient
inclusion. Secondly, we have corrected for multiple testing for multiple time-points, but no for-
mal testing for multiple testing of different sphingolipids was performed, which could be seen
as a possible limitation. The number of TA samples decreases over time which may lead to a
selection bias. This decrease is explained by the fact that some CDH infants have died and
other infants were not invasively ventilated anymore. However, due to the study design TA
sampling was only performed in ventilated infants. Our data were collected in a randomized
clinical trial and the difference in ventilation strategy could be seen as a study limitation. How-
ever, in the multivariate analysis we adjusted for the possible effect of ventilation strategy.
Table 4. (Continued)
Day 1 Day 3 Day 7 Day 14
Independent
variable
Median (IQR) p-
value
Median (IQR) p-
value
Median (IQR) p-
value
Median (IQR) p-
value
CMV 0.4 (0.3–1.1) 0.3 (0.2–0.6) 0.2 (0.1–0.4) 0.3 (0.2–1.4)
HFO 0.4 (0.3–0.8) 0.3 (0.2–0.7) 0.3 (0.1–0.8) 0.2 (0.1–0.7)
SM16:0 0.84 0.69 0.40 0.34
CMV 555.0 (316.3–
1367.5)
808.5 (517.5–
1207.5)
600.0 (173.0–
1385.0)
1115.0 (697.5–
1685.0)
HFO 760.0 (348.5–
1220.0)
908.3 (378.4–
1733.8)
1290.0 (230.5–
1862.0)
955.0 (260.0–
1670.0)
SM18:0 0.66 0.45 0.44 0.12
CMV 100.5 (54.2–297.6) 238.5 (123.4–
373.5)
134.0 (36.5–325.0) 279.5 (150.3–512.5)
HFO 144.5 (83.5–242.0) 197.4 (80.4–305.1) 223.5 (42.2–360.0) 169.0 (18.5–231.0)
SM18:1 0.72 0.39 0.84 0.09
CMV 28.8 (14.3–96.0) 41.9 (18.4–70.4) 19.0 (5.9–82.1) 30.6 (14.8–57.6)
HFO 26.6 (14.2–63.0) 38.6 (11.4–87.9) 36.5 (5.4–67.2) 16.0 (2.8–31.9)
SM24:0 0.88 0.38 0.68 0.07
CMV 244.0 (103.4–
878.8)
494.5 (241.6–
707.5)
325.5 (79.5–1020.0) 515.0 (339.8–796.3)
HFO 304.5 (128.0–
550.0)
410.5 (201.7–
630.0)
575.0 (88.0–982.0) 321.0 (40.5–453.0)
SM24:1 0.70 0.59 0.58 0.05
CMV 178.8 (83.5–890.0) 445.8 (219.3–
690.0)
299.0 (76.0–1025.0) 885.0 (444.8–
1472.5)
HFO 245.5 (115.0–
419.5)
377.3 (142.6–
880.0)
605.0 (96.0–1036.0) 380.0 (100.0–775.0)
Sphingolipids were expressed as ng/ mL. Abbreviations: IQR: interquartile range; Cer: ceramide; SM: sphingomyelin. The threshold for signiﬁcance was
set at 0.0125.
doi:10.1371/journal.pone.0155136.t004
Sphingolipids in CDH; An International Multicenter Study
PLOS ONE | DOI:10.1371/journal.pone.0155136 May 9, 2016 11 / 14
Third, we could only study tracheal aspirates but no lung biopsies were taken to examine gene
and protein levels of the sphingolipid pathway. Therefore, future studies should also include
lung biopsies to study those aspects. Since the sphingolipid pathway is quite complex and con-
sists of more components, such as sphingosine, sphingosine 1-phosphate (S1P) and its recep-
tors. Those components were not investigated in the current study, but have been shown in
animal studies to be involved in inflammation and lung development [22]. Therefore, future
studies may be developed to further study the sphingolipid pathway in more detail, including
its downstream targets such as VEGF, sphingosine, S1P and its receptors. Differences between
CDH infants with CDH compared to CDH infants without CLD should be studied.
In conclusion, we could not detect significant difference in temporal sphingolipid levels
antenatally diagnosed CDH infants who survived/ did not develop CLD versus nonsurvivors/
survivors who developed CLD.
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